Market Cap (In USD)
189.12 Million
Revenue (In USD)
-
Net Income (In USD)
-78.08 Million
Avg. Volume
174.58 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 6.5-19.836
- PE
- -
- EPS
- -
- Beta Value
- 0.885
- ISIN
- CA23256X1006
- CUSIP
- 23256X100
- CIK
- 1833141
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Douglas L. Drysdale
- Employee Count
- -
- Website
- https://www.cybin.com
- Ipo Date
- 2019-09-13
- Details
- Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
More Stocks
-
002360
-
3666
-
PLURPluri Inc.
PLUR
-
CSTFCuraScientific Corp
CSTF
-
TLXTalanx AG
TLX
-
CDDCardno Limited
CDD
-
084990Helixmith Co., Ltd
084990
-
OOBHFOn the Beach Group plc
OOBHF